The accompanying condensed consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”).
All material intercompany balances and transactions have been eliminated.
In February 2016, the FASB issued ASU No.
In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments”.
This update is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years.
The Company is currently evaluating the effect of this update on its consolidated financial statements.
In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230)”, requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents.
The Company is a fiscal-year end taxpayer and is required to use a blended statutory federal tax rate, inclusive of the Federal rate change enacted on December 22, 2017 to compute its effective rate for the three and six months ended December 31, 2017.
Approximately 31% and 55% of net benchtop laboratory equipment sales (48% and 30% of total revenues) for the three month periods ended December 31, 2017 and 2016, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.The Company reflected income before income tax expense of $16,400 for the three months ended December 31, 2017 compared to $64,800 for the three months ended December 31, 2016, primarily due to lack of sales of catalyst research instruments during the period and product development expenses for a new automated pill counter for the Laboratory Equipment Operations.
The Company reflected a loss before income tax benefit of $290,100 for the six months ended December 31, 2017 compared to $4,700 for the six months ended December 31, 2016 mainly due to decreased catalyst research instrument sales and product development costs as previously discussed.
As of December 31, 2017, the order backlog for catalyst research instruments was $752,500, all of which is expected to be shipped during fiscal year ending June 30, 2018, compared to $397,300 as of December 31, 2016.
The overall gross profit percentage for the three months ended December 31, 2017 was 40.5% compared to 29.6% for the three months ended December 31, 2016.
Selling expenses for the three months ended December 31, 2017 decreased $9,600 (4.3%) to $214,600 from $224,200 for the three months ended December 31, 2016, due to lower sales related expenses for the Catalyst Research Instruments Operations.
Research and development expenses increased by $27,900 (26.6%) to $132,900 for the three months ended December 31, 2017 compared to $105,000 for the three months ended December 31, 2016, primarily due to increased new product development costs incurred by the Benchtop Laboratory Equipment Operations related to the Torbal Scales Division.
Total other income decreased by $2,200 (26.5%) from $8,300 for the three months ended December 31, 2016 to $6,100 for the three months ended December 31, 2017 due to lower interest on its investment securities.